Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Targeting bone morphogenetic protein receptor 2 sensitizes lung cancer cells to TRAIL by increasing cytosolic Smac/DIABLO and the downregulation of X-linked inhibitor of apoptosis protein.

NeMoyer R, Mondal A, Vora M, Langenfeld E, Glover D, Scott M, Lairson L, Rongo C, Augeri DJ, Peng Y, Jabbour SK, Langenfeld J.

Cell Commun Signal. 2019 Nov 19;17(1):150. doi: 10.1186/s12964-019-0469-5. No abstract available.

2.

Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.

Newman JH, Augeri DJ, NeMoyer R, Malhotra J, Langenfeld E, Chesson CB, Dobias NS, Lee MJ, Tarabichi S, Jhawar SR, Bommareddy PK, Marshall S, Sadimin ET, Kerrigan JE, Goedken M, Minerowicz C, Jabbour SK, Li S, Carayannopolous MO, Zloza A, Langenfeld J.

Oncogene. 2018 Jul;37(27):3672-3685. doi: 10.1038/s41388-018-0156-9. Epub 2018 Apr 6.

PMID:
29622797
3.

Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death.

Augeri DJ, Langenfeld E, Castle M, Gilleran JA, Langenfeld J.

Mol Cancer. 2016 Apr 6;15:27. doi: 10.1186/s12943-016-0511-9.

4.
5.

Bone morphogenetic protein type I receptor antagonists decrease growth and induce cell death of lung cancer cell lines.

Langenfeld E, Hong CC, Lanke G, Langenfeld J.

PLoS One. 2013 Apr 12;8(4):e61256. doi: 10.1371/journal.pone.0061256. Print 2013.

6.

Multiple phosphorylations of cytochrome c oxidase and their functions.

Helling S, Hüttemann M, Ramzan R, Kim SH, Lee I, Müller T, Langenfeld E, Meyer HE, Kadenbach B, Vogt S, Marcus K.

Proteomics. 2012 Apr;12(7):950-9. doi: 10.1002/pmic.201100618.

7.

Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver.

Langenfeld E, Zanger UM, Jung K, Meyer HE, Marcus K.

Proteomics. 2009 May;9(9):2313-23. doi: 10.1002/pmic.200800680.

PMID:
19402041
8.

Identification of L-ferritin in neuromelanin granules of the human substantia nigra: a targeted proteomics approach.

Tribl F, Asan E, Arzberger T, Tatschner T, Langenfeld E, Meyer HE, Bringmann G, Riederer P, Gerlach M, Marcus K.

Mol Cell Proteomics. 2009 Aug;8(8):1832-8. doi: 10.1074/mcp.M900006-MCP200. Epub 2009 Mar 24.

9.

Quantitative analysis of highly homologous proteins: the challenge of assaying the "CYP-ome" by mass spectrometry.

Langenfeld E, Meyer HE, Marcus K.

Anal Bioanal Chem. 2008 Nov;392(6):1123-34. doi: 10.1007/s00216-008-2407-z. Epub 2008 Oct 10. Review.

PMID:
18846368
10.

Towards multidimensional liquid chromatography separation of proteins using fluorescence and isotope-coded protein labelling for quantitative proteomics.

Tribl F, Lohaus C, Dombert T, Langenfeld E, Piechura H, Warscheid B, Meyer HE, Marcus K.

Proteomics. 2008 Mar;8(6):1204-11. doi: 10.1002/pmic.200700736.

PMID:
18271069
11.
12.

Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5.

Langenfeld EM, Kong Y, Langenfeld J.

Oncogene. 2006 Feb 2;25(5):685-92.

PMID:
16247476
13.

Expression of bone morphogenetic proteins in human lung carcinomas.

Langenfeld EM, Bojnowski J, Perone J, Langenfeld J.

Ann Thorac Surg. 2005 Sep;80(3):1028-32.

PMID:
16122479
14.

Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors.

Langenfeld EM, Langenfeld J.

Mol Cancer Res. 2004 Mar;2(3):141-9.

15.

The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells.

Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld J.

Carcinogenesis. 2003 Sep;24(9):1445-54. Epub 2003 Jun 19.

PMID:
12819188

Supplemental Content

Loading ...
Support Center